These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38249686)

  • 1. Shared Decision-Making in the Treatment of Multiple Sclerosis: Results of a Cross-Sectional, Real-World Survey in Europe and the United States.
    Keenan A; Le HH; Gandhi K; Adedokun L; Jones E; Unsworth M; Pike J; Trenholm E
    Patient Prefer Adherence; 2024; 18():137-149. PubMed ID: 38249686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool.
    Col NF; Solomon AJ; Alvarez E; Pbert L; Ionete C; BerriosMorales I; Chester J; Kutz C; Iwuchukwu C; Livingston T; Springmann V; Col HV; Ngo LH
    Mult Scler Relat Disord; 2023 Dec; 80():105092. PubMed ID: 37931489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews.
    Gudesblatt M; Roman C; Singer BA; Schmidt H; Thomas J; Shankar SL; Lyons J; Kapadia S
    Adv Ther; 2022 Jul; 39(7):3199-3213. PubMed ID: 35556227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey.
    Nazareth TA; Rava AR; Polyakov JL; Banfe EN; Waltrip Ii RW; Zerkowski KB; Herbert LB
    Mult Scler Relat Disord; 2018 Nov; 26():219-234. PubMed ID: 30368080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Targeted Literature Search and Phenomenological Review of Perspectives of People with Multiple Sclerosis and Healthcare Professionals of the Immunology of Disease-Modifying Therapies.
    Burtchell J; Clemmons D; Clemmons J; Sabutis T; Rosenberg A; Graves J; Sweeney ML; Kramer J; Ziehn M; Brown B; Weiss JL; Obeidat AZ
    Neurol Ther; 2022 Sep; 11(3):955-979. PubMed ID: 35608740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world treatment preferences among health care providers in the United States in selecting disease modifying therapies for patients with multiple sclerosis: a discrete choice experiment.
    Bandari D; Adamson M; Bowman M; Gutierrez A; Athavale A; Oak B; Hadker N; Branco F; Geremakis C; Lewin JB; Shankar SL
    J Med Econ; 2023; 26(1):1507-1518. PubMed ID: 37934412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A qualitative systematic review of internal and external influences on shared decision-making in all health care settings.
    Truglio-Londrigan M; Slyer JT; Singleton JK; Worral P
    JBI Libr Syst Rev; 2012; 10(58):4633-4646. PubMed ID: 27820528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Patient and Clinician Assessment of Gastrointestinal (GI) Related Adverse Events Associated with Oral Disease-Modifying Therapies in Multiple Sclerosis: A Qualitative Study.
    Jivraj F; Kang S; Reedie S; Kapadia S; Strzok S; Elliott E; Cano S; Rock M
    Adv Ther; 2022 Nov; 39(11):5072-5086. PubMed ID: 36053450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
    Neuberger EE; Abbass IM; Jones E; Engmann NJ
    Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results from SPECTRUM: A survey of healthcare professionals to understand current diagnosis and management practices for secondary progressive multiple sclerosis in the United Kingdom.
    Duddy M; Wilkinson C; Medhurst S; Rhys K
    Mult Scler Relat Disord; 2021 Oct; 55():103174. PubMed ID: 34399317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future trends in multiple sclerosis management: Near East perspective.
    Hatem A; El Ayoubi NK; Habahbeh M; Ghanim Z; Al-Naqshbandi M; Raki A; Joudi H; Sahraian MA
    Mult Scler Relat Disord; 2023 Aug; 76():104800. PubMed ID: 37307691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient decision aid based on multi-criteria decision analysis for disease-modifying drugs for multiple sclerosis: prototype development.
    Kremer IEH; Jongen PJ; Evers SMAA; Hoogervorst ELJ; Verhagen WIM; Hiligsmann M
    BMC Med Inform Decis Mak; 2021 Apr; 21(1):123. PubMed ID: 33836742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shared decision-making in multiple sclerosis physical symptomatic care: a systematic review.
    Ben-Zacharia AB; Lee JM; Kahle JS; Lord B
    Ther Adv Chronic Dis; 2023; 14():20406223231172920. PubMed ID: 37324408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis.
    Stühler E; Braune S; Lionetto F; Heer Y; Jules E; Westermann C; Bergmann A; van Hövell P;
    BMC Med Res Methodol; 2020 Feb; 20(1):24. PubMed ID: 32028898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shared decision-making for people with asthma.
    Kew KM; Malik P; Aniruddhan K; Normansell R
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012330. PubMed ID: 28972652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dimethyl fumarate for multiple sclerosis.
    Xu Z; Zhang F; Sun F; Gu K; Dong S; He D
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD011076. PubMed ID: 25900414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.
    Spelman T; Herring WL; Acosta C; Hyde R; Jokubaitis VG; Pucci E; Lugaresi A; Laureys G; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Ozakbas S; Alroughani R; Kalincik T; Duquette P; Girard M; Petersen T; Patti F; Csepany T; Granella F; Grand'Maison F; Ferraro D; Karabudak R; Jose Sa M; Trojano M; van Pesch V; Van Wijmeersch B; Cartechini E; McCombe P; Gerlach O; Spitaleri D; Rozsa C; Hodgkinson S; Bergamaschi R; Gouider R; Soysal A; Castillo-Triviño ; Prevost J; Garber J; de Gans K; Ampapa R; Simo M; Sanchez-Menoyo JL; Iuliano G; Sas A; van der Walt A; John N; Gray O; Hughes S; De Luca G; Onofrj M; Buzzard K; Skibina O; Terzi M; Slee M; Solaro C; Oreja-Guevara ; Ramo-Tello C; Fragoso Y; Shaygannejad V; Moore F; Rajda C; Aguera Morales E; Butzkueven H
    J Med Econ; 2024; 27(1):109-125. PubMed ID: 38085684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whose Preferences Matter? A Patient-Centered Approach for Eliciting Treatment Goals.
    Col NF; Solomon AJ; Springmann V; Garbin CP; Ionete C; Pbert L; Alvarez E; Tierman B; Hopson A; Kutz C; Berrios Morales I; Griffin C; Phillips G; Ngo LH
    Med Decis Making; 2018 Jan; 38(1):44-55. PubMed ID: 28806143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physician and patient treatment decision-making in relapsing-remitting multiple sclerosis in Europe and the USA.
    Brown H; Gabriele S; White J
    Neurodegener Dis Manag; 2018 Dec; 8(6):371-376. PubMed ID: 30451064
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.